Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab adjuvant therapy for treating renal cell carcinoma in people at high risk of developing metastasis following nephrectomy	Atezolizumab (Tecentriq; MPDL3280A)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download
Avelumab in combination with axitinib for advanced or metastatic renal cell carcinoma – first line	Avelumab (Bavencio; MSB-0010718C) , Axitinib (Inlyta; AG-013736)	Renal cell carcinoma (RCC)	Renal Cancer	2018	View \| Download
Axitinib for Patients at High Risk of Recurrence of Renal Cell Carcinoma – Adjuvant	Axitinib (Inlyta; AG-013736)	Renal cell carcinoma (RCC)	Renal Cancer	2018	View \| Download
Belzutifan for advanced or metastatic clear cell renal cell carcinoma after 1 therapy	Belzutifan (PT2977; MK-6482)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download
Belzutifan for von Hippel-Lindau disease-associated clear cell renal cell carcinoma – first line	Belzutifan (PT2977; MK-6482)	Renal cell carcinoma (RCC)	Genetic Disorders , Oncology , Renal Cancer	2021	View \| Download
Cabozantinib with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2023	View \| Download
Lenvatinib in addition to everolimus or pembrolizumab for advanced renal cell carcinoma – First line	Everolimus (Zortress; RAD001; Afinitor; Certican; RAD-001) , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Renal cell carcinoma (RCC)	Renal Cancer	2020	View \| Download
Nivolumab adjuvant therapy for renal cell carcinoma	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2023	View \| Download
Nivolumab for adjuvant and neoadjuvant treatment of localised renal cell carcinoma	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2021	View \| Download